Targeting The Metastasis Suppressor NDRG1 For The Treatment Of Pancreatic Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$327,142.00
Summary
We will investigate NDRG1, a novel molecular target that has been demonstrated to inhibit the progression of numerous cancers. We aim to better understand the underlying functions of NDRG1 in pancreatic cancer and how we can potentially target this gene with novel therapeutics being developed in our laboratory. We hope that this new approach will lead to more promising treatment options and a better outcome for those suffering from pancreatic cancer.
Developing Microenvironment-based Prognostic Biomarkers For Early Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$132,743.00
Summary
Approximately 20% of breast cancer patients are now diagnosed with ductal carcinoma in situ (DCIS), an early stage where tumour cells are confined within the ducts of the breast and pose no threat to life. Once cells spread beyond the duct into surrounding breast tissue, risk of spread increases dramatically. This project aims to use a unique set of patient samples to identify markers that predict DCIS patients that are most at risk of spread, to personalise therapy to and reduce over-treatment.
A number of previous studies have shown high levels of two proteins, STC1 and STC2, in a substantial subset of breast cancers. We are proposing to do the first definitive analyses of whether these hormone-like proteins contribute to breast cancer growth. If yes, they are suitable targets for development of new treatments.
PRECISION: Personalised Risk Evaluation In DCIS, International
Funder
National Health and Medical Research Council
Funding Amount
$1,392,930.00
Summary
Ductal carcinoma in situ (DCIS) of the breast is a common diagnosis with problematic clinical management. This study brings together an international consortium to identify and validate clinical biomarkers of recurrence.
Identifying Novel Genome Instability Signatures In Cancer
Funder
National Health and Medical Research Council
Funding Amount
$320,891.00
Summary
Cancer is the single biggest clinical problem facing the world. An underlying hallmark of cancer is the accumulation of errors in the genetic information of a cell which arises through genomic instability. This research project aims to investigate novel molecules identified by our screening that function in response to genomic instability in cancer. This study is expected to define roles for each molecule in the maintenance of genomic stability and predict for patient diagnosis and outcome.
Towards Precision Medicine For Non-small Cell Lung Cancer
Funder
National Health and Medical Research Council
Funding Amount
$463,652.00
Summary
Better outcomes are needed for lung cancer, a disease that accounts for more cancer-related deaths than any other cancer in Australia or worldwide. My goals are to 1) develop and evaluate in clinical trials targeted therapies and immunotherapies and 2) identify clinically relevant blood and tissue based biomarkers for lung cancer patients. This combination of clinical and translational research will change practice and improve outcomes by delivering precision medicine for lung cancer patients.